CY1111194T1 - Ενωσεις πιπεριδινυλιου που επιλεκτικα προσδενουν ιντεγρινες - Google Patents
Ενωσεις πιπεριδινυλιου που επιλεκτικα προσδενουν ιντεγρινεςInfo
- Publication number
- CY1111194T1 CY1111194T1 CY20111100158T CY111100158T CY1111194T1 CY 1111194 T1 CY1111194 T1 CY 1111194T1 CY 20111100158 T CY20111100158 T CY 20111100158T CY 111100158 T CY111100158 T CY 111100158T CY 1111194 T1 CY1111194 T1 CY 1111194T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peppininyli
- universes
- optionally accessible
- accessible
- optionally
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40423902P | 2002-08-16 | 2002-08-16 | |
| EP03791686A EP1539739B1 (en) | 2002-08-16 | 2003-08-15 | Piperidinyl compounds that selectively bind integrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111194T1 true CY1111194T1 (el) | 2015-06-11 |
Family
ID=31978252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100158T CY1111194T1 (el) | 2002-08-16 | 2011-02-09 | Ενωσεις πιπεριδινυλιου που επιλεκτικα προσδενουν ιντεγρινες |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20040077684A1 (https=) |
| EP (1) | EP1539739B1 (https=) |
| JP (1) | JP4554364B2 (https=) |
| KR (1) | KR20050031464A (https=) |
| CN (1) | CN100506815C (https=) |
| AR (1) | AR041010A1 (https=) |
| AT (1) | ATE489378T1 (https=) |
| AU (2) | AU2003259891A1 (https=) |
| BR (1) | BR0313534A (https=) |
| CA (1) | CA2496127C (https=) |
| CR (1) | CR7692A (https=) |
| CY (1) | CY1111194T1 (https=) |
| DE (1) | DE60335118D1 (https=) |
| DK (1) | DK1539739T3 (https=) |
| ES (1) | ES2355139T3 (https=) |
| IL (1) | IL166534A (https=) |
| MX (1) | MXPA05001859A (https=) |
| NO (1) | NO332036B1 (https=) |
| PL (1) | PL219749B1 (https=) |
| PT (1) | PT1539739E (https=) |
| RU (1) | RU2333210C2 (https=) |
| SI (1) | SI1539739T1 (https=) |
| UA (1) | UA83467C2 (https=) |
| WO (1) | WO2004020435A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| US7351711B2 (en) | 2003-07-31 | 2008-04-01 | Janssen Pharmaceutical, N.V. | Tricyclic indanyls as integrin inhibitors |
| AU2005229015C1 (en) * | 2004-04-02 | 2013-01-17 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| EP1830902A2 (en) * | 2004-12-30 | 2007-09-12 | Cinvention Ag | Combination comprising an agent providing a signal, an implant material and a drug |
| EP1833512A1 (en) * | 2005-01-06 | 2007-09-19 | GE Healthcare AS | Optical imaging |
| US8372399B2 (en) * | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
| US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
| US8636995B2 (en) * | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
| SI2178858T1 (sl) * | 2007-08-02 | 2012-03-30 | Recordati Ireland Ltd | Nove heterociklične spojine kot mGlu antagonisti |
| WO2009058314A1 (en) | 2007-10-30 | 2009-05-07 | Janssen Pharmaceutica, N.V. | Enantioselective process for preparing a substituted alkanoic acid |
| EP2730282A1 (en) * | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| EP2456460A4 (en) | 2009-07-24 | 2013-02-20 | Univ California | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN |
| SI3050878T1 (sl) | 2013-09-24 | 2022-01-31 | Fujifilm Corporation | Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te |
| EP3512839A4 (en) | 2016-09-18 | 2020-03-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | AGAINST INTERACTION OF YAP1 WITH YCT1 INHIBITORS |
| BR112019009245A2 (pt) * | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| HRP20210228T1 (hr) * | 2016-11-08 | 2021-03-19 | Bristol-Myers Squibb Company | Amidi pirola kao inhibitori alfa v integrina |
| MA52117A (fr) * | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| BR112020018642A2 (pt) | 2018-03-14 | 2020-12-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Composto da fórmula i, composição farmacêutica, método de tratamento de câncer em um sujeito em necessidade, método de eliminação de uma célula tumoral em um sujeito |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| WO2025067433A1 (zh) * | 2023-09-28 | 2025-04-03 | 云合智药（苏州）生物科技有限公司 | 靶向整合素的化合物及其在RNAi剂中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (https=) * | 1977-06-03 | 1981-03-07 | Pfizer | |
| PT627940E (pt) * | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
| US5902795A (en) * | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
| US5340798A (en) * | 1992-10-14 | 1994-08-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5753659A (en) * | 1993-03-29 | 1998-05-19 | Zeneca Limited | Heterocyclic compouds |
| US5700801A (en) * | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| DE19516483A1 (de) * | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19613933A1 (de) * | 1996-04-06 | 1997-10-09 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| US5919792A (en) * | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
| US6211191B1 (en) * | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
| CA2315232A1 (en) * | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| AU4584199A (en) * | 1998-06-29 | 2000-01-17 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
| US6342219B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
-
2003
- 2003-08-15 AU AU2003259891A patent/AU2003259891A1/en not_active Abandoned
- 2003-08-15 JP JP2004532905A patent/JP4554364B2/ja not_active Expired - Fee Related
- 2003-08-15 AT AT03791686T patent/ATE489378T1/de active
- 2003-08-15 AR ARP030102976A patent/AR041010A1/es unknown
- 2003-08-15 KR KR1020057001657A patent/KR20050031464A/ko not_active Ceased
- 2003-08-15 RU RU2005104115/04A patent/RU2333210C2/ru not_active IP Right Cessation
- 2003-08-15 WO PCT/US2003/025782 patent/WO2004020435A1/en not_active Ceased
- 2003-08-15 CA CA2496127A patent/CA2496127C/en not_active Expired - Fee Related
- 2003-08-15 DK DK03791686.3T patent/DK1539739T3/da active
- 2003-08-15 BR BR0313534-9A patent/BR0313534A/pt not_active IP Right Cessation
- 2003-08-15 UA UAA200502396A patent/UA83467C2/uk unknown
- 2003-08-15 PT PT03791686T patent/PT1539739E/pt unknown
- 2003-08-15 CN CNB038240904A patent/CN100506815C/zh not_active Expired - Fee Related
- 2003-08-15 US US10/641,964 patent/US20040077684A1/en not_active Abandoned
- 2003-08-15 ES ES03791686T patent/ES2355139T3/es not_active Expired - Lifetime
- 2003-08-15 MX MXPA05001859A patent/MXPA05001859A/es active IP Right Grant
- 2003-08-15 SI SI200331951T patent/SI1539739T1/sl unknown
- 2003-08-15 EP EP03791686A patent/EP1539739B1/en not_active Expired - Lifetime
- 2003-08-15 DE DE60335118T patent/DE60335118D1/de not_active Expired - Lifetime
- 2003-08-15 PL PL375562A patent/PL219749B1/pl unknown
-
2005
- 2005-01-27 IL IL166534A patent/IL166534A/en not_active IP Right Cessation
- 2005-02-15 CR CR7692A patent/CR7692A/es unknown
- 2005-03-11 NO NO20051273A patent/NO332036B1/no not_active IP Right Cessation
-
2010
- 2010-10-25 AU AU2010236002A patent/AU2010236002B2/en not_active Ceased
-
2011
- 2011-02-09 CY CY20111100158T patent/CY1111194T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL375562A1 (en) | 2005-11-28 |
| EP1539739B1 (en) | 2010-11-24 |
| AR041010A1 (es) | 2005-04-27 |
| EP1539739A1 (en) | 2005-06-15 |
| KR20050031464A (ko) | 2005-04-06 |
| BR0313534A (pt) | 2005-07-12 |
| JP2005539049A (ja) | 2005-12-22 |
| CA2496127C (en) | 2012-05-29 |
| AU2010236002B2 (en) | 2012-05-03 |
| PT1539739E (pt) | 2011-01-05 |
| AU2010236002A1 (en) | 2010-11-11 |
| NO332036B1 (no) | 2012-06-04 |
| RU2333210C2 (ru) | 2008-09-10 |
| AU2003259891A1 (en) | 2004-03-19 |
| CN1688572A (zh) | 2005-10-26 |
| UA83467C2 (uk) | 2008-07-25 |
| RU2005104115A (ru) | 2005-08-27 |
| ES2355139T3 (es) | 2011-03-23 |
| WO2004020435A1 (en) | 2004-03-11 |
| IL166534A (en) | 2012-05-31 |
| IL166534A0 (en) | 2006-01-15 |
| CN100506815C (zh) | 2009-07-01 |
| SI1539739T1 (sl) | 2011-04-29 |
| PL219749B1 (pl) | 2015-07-31 |
| MXPA05001859A (es) | 2005-06-03 |
| NO20051273L (no) | 2005-05-10 |
| ATE489378T1 (de) | 2010-12-15 |
| DK1539739T3 (da) | 2011-03-07 |
| CR7692A (es) | 2009-01-14 |
| DE60335118D1 (de) | 2011-01-05 |
| US20040077684A1 (en) | 2004-04-22 |
| JP4554364B2 (ja) | 2010-09-29 |
| CA2496127A1 (en) | 2005-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111194T1 (el) | Ενωσεις πιπεριδινυλιου που επιλεκτικα προσδενουν ιντεγρινες | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| CY1105386T1 (el) | Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου | |
| EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
| DK2135881T3 (da) | Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor | |
| DE60323749D1 (de) | Substituierte pyrroline als kinase inhibitoren | |
| CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
| CY1116525T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| CY1115730T1 (el) | Θεραπευτικοι επιτοποι και χρησεις αυτων | |
| DE60120494D1 (de) | Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren | |
| CY1105395T1 (el) | Αναστολη της raf κινασης χρησιμοποιωντας αρυλικες και ετepοαρυλικες υποκατεστημενες ετepοκυκλικες ουριες | |
| DE60112611T2 (de) | Makroheterocyclische verbindungen als kinase inhibitoren | |
| CY1114554T1 (el) | Ινδαζολια, βενζοτριαζολια και ν-αναλογα αυτων ως αναστολεις p38 κινασης | |
| DK1773885T3 (da) | Humaniserede anti-c-met-antagonister | |
| ATE477254T1 (de) | Pyrrolidine als inhibitoren von iap | |
| DK1337518T3 (da) | Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren | |
| CY1112458T1 (el) | Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου | |
| DE60319364D1 (de) | Substituierte pyrroline als kinase inhibitoren | |
| CY1110020T1 (el) | Διαμορφωτες κανναβινοειδους εξαϋδρο-κυκλοοκτυλο πυραζολης | |
| NO20070324L (no) | Forbindelser og fremgangsmater for inhibering av BCL proteiner med bindingspartnere | |
| DK2161283T3 (da) | SAMMENSÆTNINGER OMFATTENDE ANTISTOFFER MOD CD79b, SOM ER KONJUGERET TIL ET VÆKSTINHIBERENDE MIDDEL ELLER ET CYTOTOKSISK MIDDEL, OG FREMGANGSMÅDER TIL BEHANDLING AF TUMOR AF HÆMATOPOIETISK OPRINDELSE | |
| ATE395082T1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
| DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
| CY1114497T1 (el) | ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5 |